Physician profile
Rex Heaton
NPI 1477627917
$15,890.62
in general payments reported to CMS, 2019-2025
72 companies · $2,931 in 2025
The $2,931 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,181 · 2022: $3,633 · 2023: $3,563 · 2024: $2,582 · 2025: $2,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,486 · Education: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,486.22 |
| Education | $589.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,601.05 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $1,036.87 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $870.21 | 2021-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $823.75 | 2021-2025 | |
| Astellas Pharma US INC | $728.34 | 2021-2025 | Padcev, Vyloy, Xtandi |
| Seagen INC. | $674.09 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Genzyme Corporation | $599.31 | 2021-2025 | |
| Daiichi Sankyo INC. | $594.01 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $517.82 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $516.72 | 2021-2025 | Opdivo |
| Eisai INC. | $489.49 | 2021-2025 | |
| Genentech USA, INC. | $481.26 | 2021-2025 | Tecentriq, Polivy, Alecensa |
| Lilly USA, LLC | $446.14 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $431.86 | 2021-2023 | Lumakras, Nplate, Xgeva |
| Incyte Corporation | $424.27 | 2021-2025 | Jakafi, Monjuvi, Niktimvo |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.07 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $352.72 | 2021-2023 | Imbruvica |
| Dendreon Pharmaceuticals LLC | $344.00 | 2021-2025 | Provenge |
| Celgene Corporation | $339.14 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Glaxosmithkline, LLC. | $334.55 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $270.20 | 2021-2025 | Trodelvy |
| Emd Serono, INC. | $261.86 | 2021-2025 | Bavencio |
| Bayer Healthcare Pharmaceuticals INC. | $251.39 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.90 | 2021-2025 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $167.14 | 2021-2025 | Libtayo |
| Myovant Sciences INC. | $164.83 | 2021-2022 | |
| Sobi, INC | $158.48 | 2022-2025 | |
| Array Biopharma INC | $132.77 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $132.27 | 2024-2025 | Iclusig, Fruzaqla |
| Sumitomo Pharma America, INC. | $131.15 | 2023-2025 | Orgovyx |
| Coherus Oncology, INC. | $116.47 | 2022-2025 | Udenyca, Loqtorzi |
| Genmab U.S., INC. | $115.07 | 2023-2025 | Tivdak, Epkinly |
| Beigene USA, INC. | $110.96 | 2023-2024 | Brukinsa |
| Karyopharm Therapeutics INC. | $101.72 | 2021-2024 | Xpovio |
| Blueprint Medicines Corporation | $97.20 | 2021-2024 | Ayvakit |
| Jazz Pharmaceuticals INC. | $95.41 | 2021-2023 | |
| Stemline Therapeutics INC. | $93.52 | 2021-2025 | Orserdu |
| Janssen Pharmaceuticals, INC | $92.67 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $89.14 | 2023-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $67.68 | 2022 | |
| Servier Pharmaceuticals LLC | $65.17 | 2022 | |
| Geron Corporation | $64.03 | 2024-2025 | Rytelo |
| Puma Biotechnology, INC. | $57.27 | 2024-2025 | |
| Deciphera Pharmaceuticals INC. | $55.56 | 2022-2025 | Qinlock, Tgct |
| Pharmaessentia USA Corporation | $54.57 | 2022-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $51.48 | 2024-2025 | Ultomiris |
| Tersera Therapeutics LLC | $43.81 | 2023-2025 | Zoladex |
| Cti Biopharma Corp. | $43.18 | 2022-2023 | Vonjo |
| G1 Therapeutics, INC. | $39.66 | 2022 | |
| Celltrion USA INC. | $37.41 | 2023 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $36.10 | 2021 | |
| Agios Pharmaceuticals, INC. | $35.43 | 2022 | |
| Csl Behring | $33.70 | 2022-2023 | Hemgenix |
| Heron Therapeutics, INC. | $32.99 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $32.01 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $31.27 | 2025 | Enjaymo |
| Exelixis INC. | $29.82 | 2024-2025 | Cabometyx |
| Acrotech Biopharma INC. | $29.53 | 2021 | |
| Morphosys, US INC. | $27.65 | 2023 | Monjuvi |
| Amneal Pharmaceuticals LLC | $25.20 | 2024 | Avastin, Neulasta, Neupogen |
| Fennec Pharmaceuticals, INC. | $23.39 | 2023 | Pedmark |
| Epizyme, INC. | $21.95 | 2021 | |
| Kyowa Kirin, INC. | $20.42 | 2021 | |
| Foundation Medicine, INC. | $20.38 | 2023 | |
| Sanofi-Aventis U.S. LLC | $19.66 | 2021 | |
| Corcept Therapeutics | $18.37 | 2025 | Korlym |
| Novocure INC. | $18.01 | 2025 | Optune Gio |
| Kite Pharma, INC. | $16.80 | 2023 | |
| Tg Therapeutics, INC. | $16.57 | 2021 | |
| Springworks Therapeutics, INC. | $15.14 | 2024 | Ogsiveo |
| Mylan Institutional INC. | $14.24 | 2023 | Ogivri |
| Pharmaand Gmbh | $3.35 | 2025 | Rubraca |
Drugs and devices associated with these payments
Keytruda $723Enhertu $490Imbruvica $340Lenvima $298Darzalex $296Verzenio $296Kisqali $295Jaypirca $277Opdivo $275Imfinzi $257Adcetris $245Padcev $235Tecentriq $228Calquence $225Orgovyx $222Lynparza $221Talvey $215Xtandi $190Elrexfio $174Tecvayli $160Epkinly $153Bosulif $151Gilotrif $146Jakafi $145Enjaymo $133Nubeqa $131Retevmo $130Libtayo $127Talzenna $125Sarclisa $125Trodelvy $124Doptelet $121Erleada $120Welireg $118Reblozyl $112Brukinsa $111Venclexta $110Inlyta $108Akeega $104Lorbrena $102Provenge $98.20Tivdak $93.96Fotivda $89.14Mektovi $86.74Iclusig $86.19Orserdu $81.71Injectafer $78.41Lumakras $73.78Polivy $69.40Braftovi $68.25Cablivi $66.88Pluvicto $66.17Rytelo $64.03Monjuvi $63.23Lupron Depot $61.50Udenyca $57.62Xpovio $57.27Keytruda Qlex $54.73Balversa $51.49Ultomiris $51.48Alecensa $49.26Stivarga $46.66Vitrakvi $46.66Fruzaqla $46.08Ojjaara $44.70Zoladex $43.81Pomalyst $43.77Rybrevant $40.15Tukysa $38.98Paxlovid $38.13Comirnaty $38.13Qinlock $37.93Vyloy $37.85Vectibix $37.78Nplate $37.78Xgeva $37.78Promacta $37.50Vegzelma $37.41Zejula $36.79Phesgo $36.72Perjeta $36.72Tagrisso $36.16Optune Gio $36.02Besremi $35.72Nerlynx $34.91Bavencio $34.18Kyprolis $32.11Cabometyx $29.82Carvykti $26.41Lutathera $25.63Neupogen $25.20Avastin $25.20Neulasta $25.20Ibrance $24.89Pedmark $23.39Elitek $23.18Piqray $22.64Jemperli $22.50Datroway $22.47Fabhalta $22.23
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Heaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.